Skip to main content

Table 2 Sample selection

From: Changes in healthcare utilization and costs associated with sildenafil therapy for pulmonary arterial hypertension: a retrospective cohort study

Criteria

Number of patients

Total number of patients with ≥1 inpatient claims, or ≥2 outpatient claims at least 30 days apart, with diagnosis of PAH during study period* and

22101

One or more pharmacy claims for Revatio during study period and

1116

≥6 months enrollment prior to index date** and

899

Eligible for medical and pharmacy benefits for duration of study period and

899

Were aged ≥18 years as of index date and

856

Were aged <65 years as of index date or

856

Were aged ≥65 years as of index date and enrolled in Medicare

856

Had total costs ≥ $0 and

855

Had no receipt of Viagra during pre-index period and

793

Had ≥6 months enrollment following index date**

567

  1. *Spanning January 1, 2005 to end of database.
  2. **Defined as the date of the first-noted claim for Revatio.